12 December 2024 in Nephrology
1 May 2025 in Kidney Research and Clinical Practice
Background: The global coronavirus disease 2019 (COVID-19) pandemic has placed patients with end-stage kidney disease (ESKD) at heightened risk owing to their vulnerability to infections. Our study focused on patients with ESKD, examining COVID-19 incidence, hospitalization, and mortality in relation to their renal replacement therapy (RRT) type and identifying factors influencing COVID-19 hospitalization. Methods: We conducted a retrospective cohort study using health insurance claims data from the Health Insurance Review and Assessment Service for patients with ESKD between July 2017 and June 2022. COVID-19 data for the general population were sourced from the Korea Disease Control and Prevention Agency. Results: Patients undergoing hemodialysis (HD) constituted 90.7% of the cohort, followed by kidney transplantation (KT) recipients and peritoneal dialysis (PD). After adjusting for every 10,000 individuals, KT recipients exhibited the highest COVID-19 incidence, followed by those undergoing HD and PD, whereas the general population showed a higher infection rate of 43.64. Patients undergoing HD had the highest hospitalization rates, followed by KT recipients and those undergoing PD. The mortality rate per 10,000 individuals was highest in HD, followed by PD, the general population, and KT. Multivariate analysis indicated that age, RRT duration, residence in a nursing hospital, and comorbidities were associated with COVID-19 hospitalization. Conclusion: Among RRT modalities, KT recipients displayed the highest COVID-19 incidence, whereas those undergoing HD exhibited the highest hospitalization and mortality rates. This study contributes to our understanding of infectious diseases in patients on RRT and aids in preparedness for future infectious disease outbreaks.
6 October 2023 in Medicine
Rationale: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematopoietic stem cell disease with features of hemolytic anemia, thrombosis, and bone marrow failure. Due to intravascular hemolysis and hemoglobinuria, renal dysfunction is often accompanied in PNH patients. Patient concerns: A 25-year old woman presenting gross hematuria after coronavirus disease 2019 infection was admitted to our medical center. She had mild nausea and headache. She was diagnosed with iron deficiency anemia few years ago and had no other underlying disease. Her laboratory findings showed acute kidney injury (AKI) and severe anemia, with evidences of hemolysis. Diagnosis: Renal biopsy was done to determine the cause of renal failure and the result was acute tubular necrosis with deposition of golden pigments, hemosiderin. With pathologic result and laboratory finding of hemolysis, we did flow cytometry for PNH, and the patient was finally diagnosed with PNH. Interventions: With AKI and oliguria, the patient started to take hemodialysis. Outcomes: After taking 5 sessions of hemodialysis, the patient’s renal function was recovered from AKI. With diagnosis of PNH, the patient is now being treated with complement C5 inhibitor. Lessons: This challenging case tells us that we should consider the first manifestation of PNH as a cause of severe AKI requiring hemodialysis in a patient with anemia and evidence of hemolysis.
1 January 2023 in Clinical and Experimental Vaccine Research
Choi H, et al. Clin Exp Vaccine Res. 2023 Jul;12(3):249-259. https://doi.org/10.7774/cevr.2023.12.3.249
14 October 2026 in BMJ Open
Introduction Hyperuricaemia is prevalent in type 2 diabetes mellitus (T2DM) and associated with adverse renal and mortality outcomes; however, existing predictive models have primarily targeted populations with diabetic nephropathy or reduced renal function, limiting their applicability to early-stage T2DM. We developed a machine learning (ML)-based model to predict incident hyperuricaemia in newly diagnosed patients with T2DM with preserved kidney function and evaluated its association with long-term cardiorenal and mortality outcomes. Research design and methods Using multicentre electronic health record databases in South Korea, ML models were developed to predict incident hyperuricaemia within 1 year of T2DM diagnosis. Model performance was externally validated across three independent databases. Based on model-derived risk stratification, 5-year risks of kidney failure, cardiovascular outcomes and all-cause mortality were evaluated. Kaplan-Meier survival analysis was used to compare cumulative incidence between risk groups in the development cohort. HRs were estimated using Cox regression and pooled using random-effects meta-analysis, with adjustment for age, sex, hypertension, insulin use and diuretic use. Results The Extreme Gradient Boosting model achieved the highest discrimination (area under the receiver operating characteristic curve: 0.769 in the development cohort (n=5263); 0.709–0.750 in external validation). In fully adjusted pooled analyses, high-risk patients exhibited significantly elevated 5-year risks of kidney failure (HR=2.47; 95% CI 1.18 to 5.18) and all-cause mortality (HR=2.56; 95% CI 1.81 to 3.62). The association with cardiovascular outcomes was attenuated after full adjustment (HR=1.12; 95% CI 0.96 to 1.30). Conclusions In newly diagnosed patients with T2DM with preserved kidney function, individuals classified as high-risk for incident hyperuricaemia by ML model were found to have higher long-term risks of kidney failure and all-cause mortality, independent of traditional risk factors. These findings suggest that model-derived hyperuricaemia risk may serve as a prognostic marker reflecting underlying renal and systemic vulnerability before overt organ damage occurs.